Importantly, we also show that administration of ACVR2B/Fc or MEK1 inhibitors prevents Folfiri-associated muscle atrophy in in vitro conditions, thus supporting the idea that promoting muscle anabolism or preventing MAPKs activation may potentially counteract chemotherapy-derived cachexia (Figure 9). The gene discussed is MAP2K1; the disease is Cachexia.